Victor L Villemagne

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/5187789/publications.pdf

Version: 2024-02-01

203	20,903	15504 65	10734 138
papers	citations	h-index	g-index

263	263	263	15647
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Amyloid Î² deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study. Lancet Neurology, The, 2013, 12, 357-367.	10.2	1,738
2	High performance plasma amyloid-Î² biomarkers for Alzheimerâ€™s disease. Nature, 2018, 554, 249-254.	27.8	1,180
3	Prevalence of Cerebral Amyloid Pathology in Persons Without Dementia. JAMA - Journal of the American Medical Association, 2015, 313, 1924.	7.4	1,166
4	Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging. Neurobiology of Aging, 2010, 31, 1275-1283.	3.1	885
5	Â-amyloid imaging and memory in non-demented individuals: evidence for preclinical Alzheimer's disease. Brain, 2007, 130, 2837-2844.	7.6	739
6	Longitudinal assessment of AÎ² and cognition in aging and Alzheimer disease. Annals of Neurology, 2011, 69, 181-192.	5.3	730
7	The Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging: methodology and baseline characteristics of 1112 individuals recruited for a longitudinal study of Alzheimer's disease. International Psychogeriatrics, 2009, 21, 672-687.	1.0	661
8	Imaging of amyloid Î² in Alzheimer's disease with 18F-BAY94-9172, a novel PET tracer: proof of mechanism. Lancet Neurology, The, 2008, 7, 129-135.	10.2	631
9	Prevalence of Amyloid PET Positivity in Dementia Syndromes. JAMA - Journal of the American Medical Association, 2015, 313, 1939.	7.4	501
10	The Amyloid-Î² Pathway in Alzheimerâ€™s Disease. Molecular Psychiatry, 2021, 26, 5481-5503.	7.9	478
11	Tau imaging: early progress and future directions. Lancet Neurology, The, 2015, 14, 114-124.	10.2	432
12	Relationship between atrophy and Î²â€amyloid deposition in Alzheimer disease. Annals of Neurology, 2010, 67, 317-324.	5.3	322
13	Imaging tau and amyloid-Î² proteinopathies in Alzheimer disease and other conditions. Nature Reviews Neurology, 2018, 14, 225-236.	10.1	321
14	Amyloid Imaging with ¹⁸F-Florbetaben in Alzheimer Disease and Other Dementias. Journal of Nuclear Medicine, 2011, 52, 1210-1217.	5.0	311
15	Regional variability of imaging biomarkers in autosomal dominant Alzheimerâ€™s disease. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, E4502-9.	7.1	309
16	18F-THK523: a novel in vivo tau imaging ligand for Alzheimer's disease. Brain, 2011, 134, 1089-1100.	7.6	299
17	Subtypes of progressive aphasia: application of the international consensus criteria and validation using Î²-amyloid imaging. Brain, 2011, 134, 3030-3043.	7.6	294
18	Novel ¹⁸F-Labeled Arylquinoline Derivatives for Noninvasive Imaging of Tau Pathology in Alzheimer Disease. Journal of Nuclear Medicine, 2013, 54, 1420-1427.	5.0	259

#	Article	IF	Citations
19	Amyloid-PET and 18F-FDG-PET in the diagnostic investigation of Alzheimer's disease and other dementias. Lancet Neurology, The, 2020, 19, 951-962.	10.2	254
20	Non-invasive assessment of Alzheimerâ€™s disease neurofibrillary pathology using 18F-THK5105 PET. Brain, 2014, 137, 1762-1771.	7.6	234
21	Brain Amyloid Imaging. Journal of Nuclear Medicine, 2011, 52, 1733-1740.	5.0	226
22	Fibre-specific white matter reductions in Alzheimerâ€™s disease and mild cognitive impairment. Brain, 2018, 141, 888-902.	7.6	226
23	Regional dynamics of amyloid-Î² deposition in healthy elderly, mild cognitive impairment and Alzheimerâ€™s disease: a voxelwise PiBâ€“PET longitudinal study. Brain, 2012, 135, 2126-2139.	7.6	222
24	Cerebral quantitative susceptibility mapping predicts amyloid-Î²-related cognitive decline. Brain, 2017, 140, 2112-2119.	7.6	213
25	Molecular mechanisms for Alzheimer's disease: implications for neuroimaging and therapeutics. Journal of Neurochemistry, 2006, 97, 1700-1725.	3.9	206
26	Predicting Alzheimer disease with Î²â€amyloid imaging: Results from the Australian imaging, biomarkers, and lifestyle study of ageing. Annals of Neurology, 2013, 74, 905-913.	5.3	194
27	Cerebral Microbleeds: A Review of Clinical, Genetic, and Neuroimaging Associations. Frontiers in Neurology, 2014, 4, 205.	2.4	176
28	Clinical and cognitive trajectories in cognitively healthy elderly individuals with suspected non-Alzheimer's disease pathophysiology (SNAP) or Alzheimer's disease pathology: a longitudinal study. Lancet Neurology, The, 2016, 15, 1044-1053.	10.2	175
29	Cross-sectional and Longitudinal Analysis of the Relationship Between AÎ² Deposition, Cortical Thickness, and Memory in Cognitively Unimpaired Individuals and in Alzheimer Disease. JAMA Neurology, 2013, 70, 903.	9.0	170
30	Sex, amyloid, and APOE Îµ4 and risk of cognitive decline in preclinical Alzheimer's disease: Findings from three wellâ€characterized cohorts. Alzheimer's and Dementia, 2018, 14, 1193-1203.	0.8	169
31	Comparison of 11C-PiB and 18F-florbetaben for AÎ² imaging in ageing and Alzheimerâ€™s disease. European Journal of Nuclear Medicine and Molecular Imaging, 2012, 39, 983-989.	6.4	161
32	Amyloid-Î², Anxiety, and Cognitive Decline in Preclinical Alzheimer Disease. JAMA Psychiatry, 2015, 72, 284.	11.0	160
33	High Striatal Amyloid Î²-Peptide Deposition Across Different Autosomal Alzheimer Disease Mutation Types. Archives of Neurology, 2009, 66, 1537-44.	4.5	156
34	In vivo evaluation of a novel tau imaging tracer for Alzheimerâ€™s disease. European Journal of Nuclear Medicine and Molecular Imaging, 2014, 41, 816-826.	6.4	156
35	Multisite study of the relationships between antemortem [¹¹C]PIBâ€PET Centiloid values and postmortem measures of Alzheimer's disease neuropathology. Alzheimer's and Dementia, 2019, 15, 205-216.	0.8	155
36	In VitroCharacterization of Pittsburgh Compound-B Binding to Lewy Bodies. Journal of Neuroscience, 2007, 27, 10365-10371.	3.6	154

#	Article	IF	Citations
37	Head-to-Head Comparison of ¹¹C-PiB and ¹⁸F-AZD4694 (NAV4694) for Î²-Amyloid Imaging in Aging and Dementia. Journal of Nuclear Medicine, 2013, 54, 880-886.	5.0	145
38	Assessment of ¹⁸F-PI-2620 as a Biomarker in Progressive Supranuclear Palsy. JAMA Neurology, 2020, 77, 1408.	9.0	145
39	Four-repeat tauopathies. Progress in Neurobiology, 2019, 180, 101644.	5.7	141
40	Cognition and beta-amyloid in preclinical Alzheimer's disease: Data from the AIBL study. Neuropsychologia, 2011, 49, 2384-2390.	1.6	139
41	Subjective memory decline predicts greater rates of clinical progression in preclinical Alzheimer's disease. Alzheimer's and Dementia, 2016, 12, 796-804.	0.8	135
42	Association of Cerebral Amyloid-Î² Aggregation With Cognitive Functioning in Persons Without Dementia. JAMA Psychiatry, 2018, 75, 84.	11.0	133
43	Independent contribution of temporal Î²-amyloid deposition to memory decline in the pre-dementia phase of Alzheimerâ€™s disease. Brain, 2011, 134, 798-807.	7.6	132
44	Larger temporal volume in elderly with high versus low beta-amyloid deposition. Brain, 2010, 133, 3349-3358.	7.6	130
45	Plasma amyloid Î² 42/40 ratios as biomarkers for amyloid Î² cerebral deposition in cognitively normal individuals. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2017, 8, 179-187.	2.4	129
46	Changes in plasma amyloid beta in a longitudinal study of aging and Alzheimer's disease. Alzheimer's and Dementia, 2014, 10, 53-61.	0.8	114
47	BDNF Val66Met, AÎ² amyloid, and cognitive decline in preclinical Alzheimer's disease. Neurobiology of Aging, 2013, 34, 2457-2464.	3.1	109
48	Total AÎ² ₄₂ /AÎ² ₄₀ ratio in plasma predicts amyloid-PET status, independent of clinical AD diagnosis. Neurology, 2020, 94, e1580-e1591.	1.1	102
49	Comparison of MR-less PiB SUVR quantification methods. Neurobiology of Aging, 2015, 36, S159-S166.	3.1	96
50	AÎ²-amyloid and Tau Imaging in Dementia. Seminars in Nuclear Medicine, 2017, 47, 75-88.	4.6	96
51	The ART of Loss: AÎ² Imaging in the Evaluation of Alzheimerâ€™s Disease and other Dementias. Molecular Neurobiology, 2008, 38, 1-15.	4.0	94
52	Implementing the centiloid transformation for 11C-PiB and Î²-amyloid 18F-PET tracers using CapAIBL. NeuroImage, 2018, 183, 387-393.	4.2	94
53	Genetic variation in Aquaporin-4 moderates the relationship between sleep and brain AÎ²-amyloid burden. Translational Psychiatry, 2018, 8, 47.	4.8	92
54	Basal forebrain atrophy correlates with amyloid Î² burden in Alzheimer's disease. NeuroImage: Clinical, 2015, 7, 105-113.	2.7	89

#	Article	IF	Citations
55	18F-Florbetaben PET beta-amyloid binding expressed in Centiloids. European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44, 2053-2059.	6.4	87
56	InÂvivo tau imaging: Obstacles and progress. , 2014, 10, S254-S264.		84
57	The challenges of tau imaging. Future Neurology, 2012, 7, 409-421.	0.5	82
58	Appearance modeling of 11C PiB PET images: Characterizing amyloid deposition in Alzheimer's disease, mild cognitive impairment and healthy aging. NeuroImage, 2008, 43, 430-439.	4.2	81
59	Standardized Expression of ¹⁸F-NAV4694 and ¹¹C-PiB Î²-Amyloid PET Results with the Centiloid Scale. Journal of Nuclear Medicine, 2016, 57, 1233-1237.	5.0	80
60	AÎ² imaging with 18F-florbetaben in prodromal Alzheimer's disease: a prospective outcome study. Journal of Neurology, Neurosurgery and Psychiatry, 2015, 86, 431-436.	1.9	78
61	Effect of BDNF Val66Met on Memory Decline and Hippocampal Atrophy in Prodromal Alzheimerâ€™s Disease: A Preliminary Study. PLoS ONE, 2014, 9, e86498.	2.5	75
62	APOE Îµ4 moderates amyloid-related memory decline in preclinical Alzheimer's disease. Neurobiology of Aging, 2015, 36, 1239-1244.	3.1	75
63	Comparison of amyloid PET measured in Centiloid units with neuropathological findings in Alzheimerâ€™s disease. Alzheimer's Research and Therapy, 2020, 12, 22.	6.2	74
64	Evaluating Atypical Dementia Syndromes Using Positron Emission Tomography With Carbon 11â€“Labeled Pittsburgh Compound B. Archives of Neurology, 2007, 64, 1140.	4.5	72
65	Sensitivity of composite scores to amyloid burden in preclinical Alzheimer's disease: Introducing the Zâ€scores of Attention, Verbal fluency, and Episodic memory for Nondemented older adults composite score. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2016, 2, 19-26.	2.4	72
66	Trajectories of memory decline in preclinical Alzheimer's disease: results from the Australian Imaging, Biomarkers and Lifestyle Flagship Study of Ageing. Neurobiology of Aging, 2015, 36, 1231-1238.	3.1	71
67	Association of Î²-Amyloid and Apolipoprotein E Îµ4 With Memory Decline in Preclinical Alzheimer Disease. JAMA Neurology, 2018, 75, 488.	9.0	70
68	Assessing THK523 selectivity for tau deposits in Alzheimerâ€™s disease and nonâ€“Alzheimerâ€™s disease tauopathies. Alzheimer's Research and Therapy, 2014, 6, 11.	6.2	68
69	AÎ² and cognitive change: Examining the preclinical and prodromal stages of Alzheimer's disease. Alzheimer's and Dementia, 2014, 10, 743.	0.8	66
70	Tau imaging in the study of ageing, Alzheimer's disease, and other neurodegenerative conditions. Current Opinion in Neurobiology, 2016, 36, 43-51.	4.2	66
71	Amyloid-Î² Related Memory Decline is not Associated with Subjective or Informant Rated Cognitive Impairment in Healthy Adults. Journal of Alzheimer's Disease, 2014, 43, 677-686.	2.6	63
72	A plasma protein classifier for predicting amyloid burden for preclinical Alzheimerâ€™s disease. Science Advances, 2019, 5, eaau7220.	10.3	59

#	Article	IF	Citations
73	Fifteen Years of the Australian Imaging, Biomarkers and Lifestyle (AIBL) Study: Progress and Observations from 2,359 Older Adults Spanning the Spectrum from Cognitive Normality to Alzheimerâ€™s Disease. Journal of Alzheimer's Disease Reports, 2021, 5, 443-468.	2.2	59
74	Influence of BDNF Val66Met on the relationship between physical activity and brain volume. Neurology, 2014, 83, 1345-1352.	1.1	58
75	Atrophy, hypometabolism and clinical trajectories in patients with amyloid-negative Alzheimerâ€™s disease. Brain, 2016, 139, 2528-2539.	7.6	58
76	AÎ² Imaging: feasible, pertinent, and vital to progress in Alzheimerâ€™s disease. European Journal of Nuclear Medicine and Molecular Imaging, 2012, 39, 209-219.	6.4	55
77	Centiloid scaling for quantification of brain amyloid with [18F]flutemetamol using multiple processing methods. EJNMMI Research, 2018, 8, 107.	2.5	55
78	In vitro characterization of [18F]-florbetaben, an AÎ² imaging radiotracer. Nuclear Medicine and Biology, 2012, 39, 1042-1048.	0.6	54
79	Imaginem oblivionis: the prospects of neuroimaging for early detection of Alzheimer's disease. Journal of Clinical Neuroscience, 2005, 12, 221-230.	1.5	51
80	AÎ² amyloid, cognition, and APOE genotype in healthy older adults. Alzheimer's and Dementia, 2013, 9, 538-545.	0.8	51
81	Tau positron emission tomography using [18F]THK5351 and cerebral glucose hypometabolism in Alzheimer's disease. Neurobiology of Aging, 2017, 59, 210-219.	3.1	50
82	Comparison of ¹⁸Fâ€florbetaben quantification results using the standard Centiloid, MRâ€based, and MRâ€less CapAIBL^{Â®} approaches: Validation against histopathology. Alzheimer's and Dementia, 2019, 15, 807-816.	0.8	50
83	18F-florbetaben AÎ² imaging in mild cognitive impairment. Alzheimer's Research and Therapy, 2013, 5, 4.	6.2	49
84	Amyloid burden and incident depressive symptoms in cognitively normal older adults. International Journal of Geriatric Psychiatry, 2017, 32, 455-463.	2.7	49
85	Optimal Reference Region to Measure Longitudinal Amyloid-Î² Change with ¹⁸F-Florbetaben PET. Journal of Nuclear Medicine, 2017, 58, 1300-1306.	5.0	49
86	Alzheimerâ€™s Disease Normative Cerebrospinal Fluid Biomarkers Validated inÂPET Amyloid-Î² Characterized Subjects from the Australian Imaging, Biomarkers andÂLifestyle (AIBL) study. Journal of Alzheimer's Disease, 2015, 48, 175-187.	2.6	47
87	Cortical [<scp>¹⁸F</scp>]<scp>PI</scp>â€2620 Binding Differentiates Corticobasal Syndrome Subtypes. Movement Disorders, 2021, 36, 2104-2115.	3.9	46
88	MR-Less Surface-Based Amyloid Assessment Based on 11C PiB PET. PLoS ONE, 2014, 9, e84777.	2.5	43
89	Amyloid imaging: Past, present and future perspectives. Ageing Research Reviews, 2016, 30, 95-106.	10.9	43
90	Relationships Between Performance on the Cogstate Brief Battery, Neurodegeneration, and AÂ Accumulation in Cognitively Normal Older Adults and Adults with MCI. Archives of Clinical Neuropsychology, 2015, 30, 49-58.	0.5	40

#	Article	IF	Citations
91	Innate phagocytosis by peripheral blood monocytes is altered in Alzheimerâ€™s disease. Acta Neuropathologica, 2016, 132, 377-389.	7.7	40
92	Elecsys CSF biomarker immunoassays demonstrate concordance with amyloid-PET imaging. Alzheimer's Research and Therapy, 2020, 12, 36.	6.2	39
93	Direct Comparison of the Tau PET Tracers¹⁸F-Flortaucipir and¹⁸F-MK-6240 in Human Subjects. Journal of Nuclear Medicine, 2022, 63, 108-116.	5.0	39
94	In Vivo Assessment of Vesicular Monoamine Transporter Type 2 in Dementia With Lewy Bodies and Alzheimer Disease. Archives of Neurology, 2011, 68, 905.	4.5	38
95	Assessment of amyloid Î² in pathologically confirmed frontotemporal dementia syndromes. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2017, 9, 10-20.	2.4	38
96	Differential Diagnosis in AlzheimerÂ's Disease and Dementia with Lewy Bodies via VMAT2 and Amyloid Imaging. Neurodegenerative Diseases, 2012, 10, 161-165.	1.4	37
97	AÎ²-related memory decline in APOE Îµ4 noncarriers. Neurology, 2016, 86, 1635-1642.	1.1	37
98	A Conceptualization of the Utility of Subjective Cognitive Decline in Clinical Trials of Preclinical Alzheimerâ€™s Disease. Journal of Molecular Neuroscience, 2016, 60, 354-361.	2.3	37
99	Chronic stress and <scp>A</scp>lzheimer's disease: theâ€‰interplay between the hypothalamicâ€“pituitaryâ€“adrenal axis, genetics and microglia. Biological Reviews, 2021, 96, 2209-2228.	10.4	37
100	Non-Verbal Episodic Memory Deficits in Primary Progressive Aphasias are Highly Predictive of Underlying Amyloid Pathology. Journal of Alzheimer's Disease, 2016, 51, 367-376.	2.6	37
101	Early-phase [18F]PI-2620 tau-PET imaging as a surrogate marker of neuronal injury. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 2911-2922.	6.4	36
102	Computer-aided detection of cerebral microbleeds in susceptibility-weighted imaging. Computerized Medical Imaging and Graphics, 2015, 46, 269-276.	5.8	35
103	Effect of APOE Genotype on Amyloid Deposition, Brain Volume, and Memory in Cognitively Normal Older Individuals. Journal of Alzheimer's Disease, 2017, 58, 1293-1302.	2.6	35
104	Acceleration of hippocampal atrophy rates in asymptomatic amyloidosis. Neurobiology of Aging, 2016, 39, 99-107.	3.1	34
105	Association of Î²-Amyloid Level, Clinical Progression, and Longitudinal Cognitive Change in Normal Older Individuals. Neurology, 2021, 96, e662-e670.	1.1	34
106	Positron Emission Tomographic Imaging in Stroke. Stroke, 2016, 47, 113-119.	2.0	33
107	Neuroimaging biomarkers in Alzheimerâ€™s disease and other dementias. Ageing Research Reviews, 2016, 30, 4-16.	10.9	32
108	Plasma Cortisol, Brain Amyloid-Î², and Cognitive Decline in Preclinical Alzheimerâ€™s Disease: A 6-Year Prospective Cohort Study. Biological Psychiatry: Cognitive Neuroscience and Neuroimaging, 2017, 2, 45-52.	1.5	32

#	Article	IF	Citations
109	Impact of APOE-Îµ4 carriage on the onset and rates of neocortical AÎ²-amyloid deposition. Neurobiology of Aging, 2020, 95, 46-55.	3.1	32
110	KIBRA is associated with accelerated cognitive decline and hippocampal atrophy in APOE Îµ4-positive cognitively normal adults with high AÎ²-amyloid burden. Scientific Reports, 2018, 8, 2034.	3.3	31
111	Advances in Brain Amyloid Imaging. Seminars in Nuclear Medicine, 2021, 51, 241-252.	4.6	30
112	Relationship between amyloid and tau levels and its impact on tau spreading. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 2225-2232.	6.4	30
113	First-in-Humans Evaluation of ¹⁸F-SMBT-1, a Novel ¹⁸F-Labeled Monoamine Oxidase-B PET Tracer for Imaging Reactive Astrogliosis. Journal of Nuclear Medicine, 2022, 63, 1551-1559.	5.0	30
114	Assessing Reactive Astrogliosis with ¹⁸F-SMBT-1 Across the Alzheimer Disease Spectrum. Journal of Nuclear Medicine, 2022, 63, 1560-1569.	5.0	29
115	Effect of a 24-month physical activity program on brain changes in older adults at risk of Alzheimer's disease: the AIBL active trial. Neurobiology of Aging, 2020, 89, 132-141.	3.1	28
116	Amyloid burden and incident depressive symptoms in preclinical Alzheimerâ€™s disease. Journal of Affective Disorders, 2018, 229, 269-274.	4.1	27
117	Utility of an Alzheimerâ€™s Disease Risk-Weighted Polygenic Risk Score for Predicting Rates of Cognitive Decline in Preclinical Alzheimerâ€™s Disease: A Prospective Longitudinal Study. Journal of Alzheimer's Disease, 2018, 66, 1193-1211.	2.6	27
118	Plasma Amyloid-Î² Biomarker Associated with Cognitive Decline in Preclinical Alzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2020, 77, 1057-1065.	2.6	27
119	Molecular Imaging Approaches in Dementia. Radiology, 2021, 298, 517-530.	7.3	27
120	Predicting Alzheimer disease from a blood-based biomarker profile. Neurology, 2016, 87, 1093-1101.	1.1	26
121	Association of naturally occurring antibodies to Î²-amyloid with cognitive decline and cerebral amyloidosis in Alzheimerâ€™s disease. Science Advances, 2021, 7, .	10.3	26
122	Early detection of amyloid load using 18F-florbetaben PET. Alzheimer's Research and Therapy, 2021, 13, 67.	6.2	26
123	Î²-Amyloid, APOE and BDNF Genotype, and Depressive and Anxiety Symptoms in Cognitively Normal Older Women and Men. American Journal of Geriatric Psychiatry, 2016, 24, 1191-1195.	1.2	25
124	Imaging of Reactive Astrogliosis by Positron Emission Tomography. Frontiers in Neuroscience, 2022, 16, 807435.	2.8	25
125	Amyloid PET Ligands for Dementia. PET Clinics, 2010, 5, 33-53.	3.0	23
126	A â€˜Disease Severity Indexâ€™ to identify individuals with Subjective Memory Decline who will progress to mild cognitive impairment or dementia. Scientific Reports, 2017, 7, 44368.	3.3	23

#	Article	IF	Citations
127	Klotho allele status is not associated with AÎ² and APOE Îµ4â€“related cognitive decline in preclinical Alzheimer's disease. Neurobiology of Aging, 2019, 76, 162-165.	3.1	23
128	Relationships Between Plasma Lipids Species, Gender, Risk Factors, and Alzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2020, 76, 303-315.	2.6	23
129	Mesial temporal tau is related to worse cognitive performance and greater neocortical tau load in amyloid-Î²â€“negative cognitively normal individuals. Neurobiology of Aging, 2021, 97, 41-48.	3.1	23
130	Amyloid-Related Memory Decline in Preclinical Alzheimerâ€™s Disease Is Dependent on APOE Îµ4 and Is Detectable over 18-Months. PLoS ONE, 2015, 10, e0139082.	2.5	22
131	Efficient machine learning framework for computer-aided detection of cerebral microbleeds using the Radon transform. , 2014, , .		21
132	Concordance Between Cerebrospinal Fluid Biomarkers with Alzheimerâ€™s Disease Pathology Between Three Independent Assay Platforms. Journal of Alzheimer's Disease, 2017, 61, 169-183.	2.6	21
133	Rates of ageâ€•and amyloid Î²â€•associated cortical atrophy in older adults with superior memory performance. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2019, 11, 566-575.	2.4	21
134	What Is T+? A Gordian Knot of Tracers, Thresholds, and Topographies. Journal of Nuclear Medicine, 2021, 62, 614-619.	5.0	21
135	Targeting metals rescues the phenotype in an animal model of tauopathy. Metallomics, 2018, 10, 1339-1347.	2.4	20
136	Plasma metabolites associated with biomarker evidence of neurodegeneration in cognitively normal older adults. Journal of Neurochemistry, 2021, 159, 389-402.	3.9	20
137	Amyloid Î²â€“associated cognitive decline in the absence of clinical disease progression and systemic illness. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2017, 8, 156-164.	2.4	19
138	Relationship Between Amyloid-Î² Positivity and Progression to Mild Cognitive Impairment or Dementia over 8 Years in Cognitively Normal Older Adults. Journal of Alzheimer's Disease, 2018, 65, 1313-1325.	2.6	19
139	In vivo microstructural heterogeneity of white matter lesions in healthy elderly and Alzheimer's disease participants using tissue compositional analysis of diffusion MRI data. NeuroImage: Clinical, 2020, 28, 102479.	2.7	19
140	Plasma transferrin and hemopexin are associated with altered AÎ² uptake and cognitive decline in Alzheimerâ€™s disease pathology. Alzheimer's Research and Therapy, 2020, 12, 72.	6.2	19
141	Sensitivity of a Preclinical Alzheimerâ€™s Cognitive Composite (PACC) to amyloid Î² load in preclinical Alzheimerâ€™s disease. Journal of Clinical and Experimental Neuropsychology, 2019, 41, 591-600.	1.3	18
142	Selective Tau Imaging: Der Stand der Dinge. Journal of Nuclear Medicine, 2018, 59, 175-176.	5.0	17
143	Comparing cortical signatures of atrophy between late-onset and autosomal dominant Alzheimer disease. NeuroImage: Clinical, 2020, 28, 102491.	2.7	17
144	Higher Coffee Consumption Is Associated With Slower Cognitive Decline and Less Cerebral AÎ²-Amyloid Accumulation Over 126 Months: Data From the Australian Imaging, Biomarkers, and Lifestyle Study. Frontiers in Aging Neuroscience, 2021, 13, 744872.	3.4	17

#	Article	IF	Citations
145	A Polygenic Risk Score Derived From Episodic Memory Weighted Genetic Variants Is Associated With Cognitive Decline in Preclinical Alzheimerâ€™s Disease. Frontiers in Aging Neuroscience, 2018, 10, 423.	3.4	16
146	Imaging of tau deposits in adults with Niemann-Pick type C disease: a case-control study. European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46, 1132-1138.	6.4	16
147	Peripheral Î±-Defensins 1 and 2 are Elevated in Alzheimer's Disease. Journal of Alzheimer's Disease, 2015, 44, 1131-1143.	2.6	15
148	Non-negative matrix factorisation improves Centiloid robustness in longitudinal studies. NeuroImage, 2021, 226, 117593.	4.2	15
149	[¹⁸F]THK5351 PET Imaging in Patients with Mild Cognitive Impairment. Journal of Clinical		

#	Article	IF	Citations
163	IC-P-016: Amyloid imaging in therapeutic trials: The quest for the optimal reference region. , 2015, 11, P21-P22.		7
164	A harmonized longitudinal biomarkers and cognition database for assessing the natural history of preclinical Alzheimer's disease from young adulthood and for designing prevention trials. Alzheimer's and Dementia, 2019, 15, 1448-1457.	0.8	7
165	The heritability of amyloid burden in older adults: the Older Australian Twins Study. Journal of Neurology, Neurosurgery and Psychiatry, 2022, 93, 303-308.	1.9	7
166	Future Directions in Molecular Imaging of Neurodegenerative Disorders. Journal of Nuclear Medicine, 2022, 63, 68S-74S.	5.0	7
167	Visually Identified Tau 18F-MK6240 PET Patterns in Symptomatic Alzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2022, , 1-11.	2.6	7
168	CapAIBL: Automated Reporting of Cortical PET Quantification Without Need of MRI on Brain Surface Using a Patch-Based Method. Lecture Notes in Computer Science, 2016, , 109-116.	1.3	6
169	The dawn of robust individualised risk models for dementia. Lancet Neurology, The, 2019, 18, 985-987.	10.2	6
170	Local intensity model: An outlier detection framework with applications to white matter hyperintensity segmentation. , 2011, , .		5
171	Automatic detection of small spherical lesions using multiscale approach in 3D medical images. , 2013, , .		5
172	Imago Mundi, Imago AD, Imago ADNI. Alzheimer's Research and Therapy, 2014, 6, 62.	6.2	5
173	COMT val158met is not associated with AÎ²-amyloid and APOE Îµ4 related cognitive decline in cognitively normal older adults. IBRO Reports, 2019, 6, 147-152.	0.3	5
174	SPON1 Is Associated with Amyloid-Î² and APOE Îµ4-Related Cognitive Decline in Cognitively Normal Adults. Journal of Alzheimer's Disease Reports, 2021, 5, 111-120.	2.2	5
175	Insulin resistance, cognition and Alzheimer's disease biomarkers: Evidence that CSF AÎ²42 moderates the association between insulin resistance and increased CSF tau levels. Neurobiology of Aging, 2022, 114, 38-48.	3.1	5
176	Untangling tau imaging. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2016, 4, 39-42.	2.4	4
177	Reply: Cortical tau pathology: a major player in fibre-specific white matter reductions in Alzheimer's disease?. Brain, 2018, 141, e45-e45.	7.6	4
178	Comorbidity of Cerebrovascular andÂAlzheimerâ€™s Disease in Aging. Journal of Alzheimer's Disease, 2020, 78, 321-334.	2.6	4
179	ICâ€O3â€01: In vivo tau imaging in Alzheimer's disease and other dementias. Alzheimer's and Dementia, 2012, 8, P9.	0.8	3
180	Divergent Network Patterns of Amyloid-Î² Deposition in Logopenic and Amnestic Alzheimerâ€™s Disease Presentations. Biological Psychiatry: Cognitive Neuroscience and Neuroimaging, 2016, 1, 24-31.	1.5	3

#	Article	IF	Citations
181	Towards a universal cortical tau sampling mask. Alzheimer's and Dementia, 2021, 17, .	0.8	3
182	O3â€04â€05: EVALUATION OF [Fâ€18]â€Plâ€2620, A SECONDâ€GENERATION SELECTIVE TAU TRACER, FOR THE ASSESSMENT OF ALZHEIMER'S AND NONâ€ALZHEIMER'S TAUOPATHIES. Alzheimer's and Dementia, 2018, 14, P1021.	0.8	2
183	Androgen receptor CAG repeat length as a moderator of the relationship between free testosterone levels and cognition. Hormones and Behavior, 2021, 131, 104966.	2.1	2
184	Postmortem Neocortical 3H-PiB Binding and Levels of Unmodified and Pyroglutamate AÎ² in Down Syndrome and Sporadic Alzheimerâ€™s Disease. Frontiers in Aging Neuroscience, 2021, 13, 728739.	3.4	2
185	Association between amyloid-beta deposition and cortical thickness in dementia with Lewy bodies. Australian and New Zealand Journal of Psychiatry, 2023, 57, 594-602.	2.3	2
186	P1-257: DOES ENHANCED RECONSTRUCTION METHODOLOGY CHANGE THE QUANTIFICATION OF AMYLOID PET WITH FLUMETAMOL?. , 2014, 10, P401-P402.		1
187	PL-05-01: The Challenges ahead for Pet Imaging of Progressive Proteinopathies. , 2016, 12, P374-P374.		1
188	[ICâ€Pâ€165]: FIXELâ€BASED ANALYSIS OF FIBRE TRACT DEGENERATION IN MILD COGNITIVE IMPAIRMENT AND ALZHEIMER's DISEASE. Alzheimer's and Dementia, 2017, 13, P124.	0.8	1
189	Brain health correlates of mobility-related confidence. Experimental Gerontology, 2022, 163, 111776.	2.8	1
190	Relationship between amyloid and tau levels and its impact on tau spreading. Alzheimer's and Dementia, 2021, 17, .	0.8	1
191	Cerebrospinal Fluid Neurofilament Light Predicts Risk of Dementia Onset in Cognitively Healthy Individuals and Rate of Cognitive Decline in Mild Cognitive Impairment: A Prospective Longitudinal Study. Biomedicines, 2022, 10, 1045.	3.2	1
192	IC-03-01: Dynamic of beta-amyloid deposition in healthy elderly, mild cognitive impairment and alzheimer's disease: a PiB-PET longitudinal study. , 2011, 7, S6-S6.		0
193	[P4â€“134]: INSULIN RESISTANCE IS ASSOCIATED WITH REDUCTIONS IN SPECIFIC COGNITIVE DOMAINS AND INCREASES IN CSF TAU IN COGNITIVELY NORMAL ADULTS. Alzheimer's and Dementia, 2017, 13, P1308.	0.8	0
194	[P4â€“269]: COMPARISON OF ¹⁸Fâ€FLORBETABEN QUANTIFICATION RESULTS USING MRâ€BASED AND MRâ€LESS CAPAIBL: VALIDATION AGAINST HISTOPATHOLOGY. Alzheimer's and Dementia, 2017, 13, P1387.	0.8	0
195	[P4â€“499]: REFINING THE NATURAL HISTORY OF GLOBAL AND REGIONAL AÎ²â€AMYLOID DEPOSITION IN SPORADIC ALZHEIMER's DISEASE. Alzheimer's and Dementia, 2017, 13, P1530.	0.8	0
196	ICâ€Pâ€223: TO TAU OR TO MAOâ€B? MOST OF THE [Fâ€18]â€THK5351 SIGNAL IS BLOCKED BY SELEGILINE. Alzheimer's and Dementia, 2018, 14, P181.	0.8	0
197	O1â€04â€01: PRECLINICAL ALZHEIMER'S DISEASE IS ASSOCIATED WITH LEARNING IMPAIRMENTS OVER SIX DAYS: RESULTS FROM THE ONLINE REPEATED COGNITIVE ASSESSMENT (ORCA) STUDY. Alzheimer's and Dementia, 2018, 14, P223.	0.8	0
198	The trinity of tau, trauma, and time. Lancet Neurology, The, 2019, 18, 715-717.	10.2	0

#	Article	IF	Citations
199	ICâ€Pâ€004: CORRECTING FOR PET SCANNER CHANGES IN LONGITUDINAL STUDIES. Alzheimer's and Dementia, 2019, 15, P15.	0.8	0
200	Identification of Pre-Clinical Alzheimerâ€™s Disease in a Population of Elderly Cognitively Normal Participants. Journal of Alzheimer's Disease, 2020, 73, 683-693.	2.6	0
201	Comparing Pathological Risk Factors for Dementia between Cognitively Normal Japanese and Americans. Brain Sciences, 2021, 11, 1180.	2.3	0
202	AÎ² Imaging in Aging, Alzheimerâ€™s Disease, and Other Neurodegenerative Conditions. , 2021, , 283-343.		0
203	Examining the structural correlates of amyloidâ€beta in people with DLB. Alzheimer's and Dementia, 2021, 17, .	0.8	0